

Mohamed S. Al-Ibrahim, MB, ChB, F.A.C.P.

PROFESSIONAL EXPERIENCE

Dr. Al-Ibrahim serves as the President and COO of SNBL Clinical Pharmacology Center (SNBL). Dr. Al-Ibrahim joined SNBL in 2006 with over 30 years of experience in clinical research and academic medical administration. He has built a portfolio of experience in re-engineering programs, integrating medical staff and implementing new programs for improved quality and efficiencies. In his current role, Dr. Al-Ibrahim is responsible for all clinical and administrative program planning and development, quality of care oversight, medical education and medical staff development. Through his academic career at the University of Maryland Medical Center and Department of Veterans Affairs, where he maintains faculty appointments, he has compiled a vast network of resources enabling SNBL to partner with leaders in the industry for the conduct of the highest quality clinical trials. Dr. Al-Ibrahim has served as the Chairman or member of several regional and national clinical, strategic and policy making committees. He is board certified in internal medicine and infectious diseases. His areas of expertise and research interests include adult vaccine development and antibiotic effectiveness. Mohamed has written seven books and book chapters and over 20 referred journal articles.

October 2006 – present

SNBL Clinical Pharmacology Center, Inc.

Chief Operations Officer & President (August 2007 – present)

Chief Medical Officer (October 2006 – August 2007)

2004 – 2006

Maryland General Hospital (University of Maryland Medical System)

Chief Medical Officer

1994 – 2004

Department of Veterans Affairs, Maryland Health Care System

Executive Chief of Staff

1994 – 2004

University of Maryland School of Medicine

Associate Dean

1984 – 1994

University of Maryland School of Medicine

Head, Division of Internal Medicine and Geriatrics

1976 – Present

University of Maryland School of Medicine and

Baltimore Department of Veterans Affairs Medical Center

Infectious Disease Specialist

1975 – 1976
New York University School of Medicine
Assistant Professor of Medicine

ACTIVE ACADEMIC APPOINTMENTS

1990 – Present
University of Maryland School of Medicine
Clinical Professor of Medicine
Department of Medicine

ACTIVE MEDICAL STAFF APPOINTMENTS

2004 – Present
Maryland General Hospital
Department of Medicine

1983 – Present
University of Maryland Hospital
Department of Medicine

1977 – Present
Baltimore VA Medical Center
Department of Medicine

EDUCATION & TRAINING

1994
MSc, completed 15 credits towards clinical effectiveness, Harvard University, School of Public Health.

1967
MB, ChB, Baghdad College of Medicine

1962
MB, Oxford University Board

RESIDENCY TRAINING

1972 - 1973
Chief Resident in Internal Medicine, University of Maryland School of Medicine

1969-1971
Intern and Junior Assistant Resident in Medicine, Maryland General Hospital

1968-1969
Junior House Officer, The Fulham Hospital, London

RESEARCH FELLOWSHIPS

1994

Fellow, Program in Clinical Effectiveness, Harvard School of Public Health

1973 – 1975

**Fellow, Division of Infectious Diseases and Immunology
Associate Research Scientist, New York University Medical Center**

1971 – 1972

**Fellow, Division of Infectious Diseases, University of Maryland School of
Medicine**

CERTIFICATIONS & PROFESSIONAL LICENSURE

- Maryland Physician License
- 1990 – 200 Certificate of Added Qualification in Geriatric Medicine
- 1974 – Diplomat, American Board of Infectious Diseases
- 1974 – Membership, Examinations Royal College of Physicians, UK
- 1973 – Flex
- 1972 – Diplomat, American Board of Internal Medicine
- 1967 – E.C.F.M.G

MILITARY SERVICE

- 1983-2005 Colonel, Medical Corps, United States Army Reserves (Retired)

PROFESSIONAL AFFILIATIONS & MEMBERSHIPS

- Fellow, American College of Physicians
- Infectious Disease Society of America
- American Geriatric Society
- Association for Health Services Research
- Medical and Chirurgical Faculty of Maryland
- Society for General Internal Medicine
- American Public Health Association
- American Federation for Clinical Research
- Baltimore City Medical Society
- American College of Physician Executives

EDITORIAL TASKS

- Editorial Board Journal of Public Health Management and Practice
- Editorial Board Journal of Prison Health
- Reviewer Journal of American Medical Association
- Reviewer Journal of Immunological Methods
- Reviewer Cancer Treatment Reports

- Reviewer American Journal of Medical Sciences
- Reviewer Journal of Health Services Research
- Reviewer Little Brown and Co., Boston, MA

RESEARCH EXPERIENCE

2009

- A Phase I Double-Blind, placebo-controlled, single-center dose escalation study to evaluate the safety and tolerability and pharmacokinetics of intramuscular administration of a new oxime
- A Phase I, Double-blind Crossover Study of the Acute Tolerability of Immediate Extended Administration of Methotrexate in Normal Healthy Volunteers.
- A Longitudinal Study in healthy Adult Volunteers Aged 18 to 85 Years to Describe Antibody Levels to Antigens Expressed by *Staphylococcus aureus* and β -Hemolytic *Streptococci* Species, and to Describe Carriage of These Bacteria
- A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (recombinant) in Healthy Adults

2008

- An open label, single dose, randomized, active controlled, two-period, two-sequence crossover pharmacokinetics study to assess the bioequivalence of the XXXX, a XXXX transdermal formulation versus Emsam 12mg/ day after a single dose in healthy volunteers.
- A phase 1 open label placebo controlled multiple dose study to evaluate the pharmacokinetics of XXXX for injection dosed twice and three times daily in healthy subjects.
- A Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Effects of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women.
- A Phase I, Open Label, PET Study in Healthy Subjects Following a Single Oral Dose of XXXX
- An in vivo Positron Emission Tomography study of the XXXX in healthy subjects, in patients with Schizophrenia.
- A placebo-controlled, ascending multiple-dose study to evaluate the safety and pharmacokinetics of XXXX in healthy subjects.
- An Open-Label Formulation Screening Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose and Multiple Doses of Delayed Release XXXX in Healthy Subjects.
- A randomized, open-label study to assess the effect of ketoconazole on XXXX pharmacokinetics and pharmacodynamics.
- A Randomized, Double-Blind, Sequential, Ascending Multiple Dose, Placebo Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Young Male Subjects.
- A Randomized, Double-Blind, Placebo Controlled Vaccination-Challenge Study of XXXX to Determine Efficacy Against the Symptoms of Moderate to Severe *Campylobacter jejuni* Infection in Normal Healthy Volunteers.
- Single dose pharmacokinetics and safety/tolerability of two formulations of XXXX transdermal systems compared to oral XXXX in healthy volunteers
- An open-label study to assess the effect of XXXX inducers on XXXX pharmacokinetics and pharmacodynamics

- Additional cohort - A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Rising Dose, Safety, Tolerability and Pharmacokinetic Study of XXXX When Administered to Normal Healthy Adult Volunteers
- A Three Part Study In Healthy Males and Females Assessing the Relative Bioavailability and Food Effect of Two Formulations of XXXX, the Estimated Bioavailability of XXXX, The Single and Repeat Dose Safety, Tolerability and Pharmacokinetics of Escalating Dose
- A randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Effects of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women.
- An open-label Phase I multiple dose trial to assess the safety, tolerability and efficacy of capsules containing cross-linked polyelectrolyte giving to ESRD patient.
- A 2-Period, 2-Panel, Double-Blind, Randomized, Placebo-Controlled Pilot Study of Experimental Models for the Assessment of the Perception of Potentially Injurious Heat in Household Settings After the Administration of XXXX in Healthy Subjects
- A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of XXXX When Compared With Valsartan and Olmesartan in Subjects with Essential Hypertension
- A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Rising Dose, Safety, Tolerability and Pharmacokinetic Study of XXXX When Administered to Normal Healthy Adult Volunteers
- A multiple-center, single-ascending dose, randomized, observer-blinded, placebo-controlled, study to investigate the safety, tolerability, and pharmacokinetics of XXXX following intravenous administration in individuals with allergic rhinitis.
- A Phase II Dose Finding Study with XXXX in Subjects with Recurrent Episodes of Genital Herpes
- An open label, randomized assessment of the relative bioavailability of a single dose of XXXX administered as a 15mg tablet, one 5 mg tablet or five 1 mg tablets compared with the 15 mg capsule and the effect of a high fat meal on the bioavailability of
- An open-label, dose escalating study to evaluate the safety of intravaginal oxybutynin in subjects with urge urinary incontinence

2007

- A single-center, randomized, double-blind, placebo-controlled, single-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of XXXX administered to healthy, postmenopausal volunteers.
- A Phase I, double-blind, placebo-controlled, randomized study to assess the safety, tolerability and pharmacokinetics of single escalating doses of XXX in healthy volunteers
- A phase I study, assessing the pharmacokinetics of two formulations of Oxycodone and XXX compared with Oxycodone XXX consumed after chewing and with Oxycontin.
- An open-label, multiple-dose interaction study between XXXX and Metformin or Probenecid in healthy adult subjects.
- A Phase 1B, randomized, placebo-controlled clinical trial to study the safety and efficacy of XXXX in Hepatitis C infected patients.
- An open-label, non-randomized, one sequence, multi-center study to assess the effects of an oral contraceptive on the pharmacokinetics of XXXX in healthy female subjects
- A Pilot Single-Dose Study of the pharmacokinetics of two XXXX Fentanyl Transdermal Systems Compared to XXXX in Healthy Subjects.
- Single Dose Pharmacokinetics and Safety/Tolerability of Pramipexole Transdermal Systems Compared to Oral Pramipexole in Healthy Volunteers
- Randomized, single-center, open-label, 2-way crossover, 2-arm study with 3 treatments and 2 periods lasting 7 days each, minimum 7 day washout to determine the relative bioavailability of two XXXX Transdermal systems and to assess the wear characteristics

- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Determine the Safety, Pharmacokinetic Effects, and Efficacy of XXXX in Patients with Hypercholesterolemia.
- An in vivo Positron Emission Tomography study of the XXXX in healthy subjects, in patients with Alzheimer's disease.
- An in vivo Positron Emission Tomography study of the XXXX in healthy subjects, in patients with Schizophrenia.
- A phase I open-label, single ascending dose study of the safety, nasal tolerability and pharmacokinetics of XXXX intranasal granisetron delivered by XXXX in healthy volunteers.
- A placebo-controlled, ascending single-dose study to evaluate the safety and pharmacokinetics of XXXX in healthy subjects.
- A phase I, double-blinded study to evaluate the safety, tolerability, and immunogenicity of Pandemic Influenza plasmid DNA vaccines administered with the XXXX needle-free System.
- A phase I study to evaluate the safety, tolerability and immunogenicity of the pandemic influenza vaccines XXXX and XXXX.
- Single-dose, randomized, three-period cross over design study of the XXXX compared with the XXXX.
- A Phase II randomized, placebo-controlled clinical trial to study the safety and efficacy of XXXX in hepatitis C infected patients.
- A 52-Week, Randomized, Double-Blind, Parallel-group, Multi-center, Phase IIIB Study Comparing the Long-term Safety of XXXX Actuations Twice Daily to XXXX Actuations Twice Daily in Adult and Adolescent African American Subjects with Asthma
- Multi-center, randomized, double-blind active controlled parallel group study to investigate plasma folate, red blood cell folate and homocysteine levels during a 24 week oral administration of an OC containing folate compared to OC alone.
- A randomized, Double-Blind, Active-and Placebo-Controlled, Parallel- Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of XXXX Immediate-Release Formulation in Subjects Awaiting Primary Joint Replacement Surgery for End-Stage
- Blood draw to obtain the PBMC layer of cells from whole blood from MS patients
- A Multicenter, randomized, double-blind study to compare the efficacy and safety of patient-initiated XXXX to XXXX in immunocompetent adults with recurrent genital herpes.
- A Prospective, Multi-center Trial of XXXX Compared to Best Standard of Care in Patients with Progressive or Recurrent GBM.
- A Randomized, Double-Blind, Multiple-Site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of XXXX Compared to XXXX in Patients with Moderate to Severe Acne Vulgaris.
- A randomized, double-blind, Phase III study of the efficacy and safety to XXXX in subjects requiring NSAID treatment.
- Analysis of protein or RNA Levels of the Glutamate Transporters, XXXX.
- Efficacy and safety of 2 mg/day of XXXX on Sleep Maintenance Insomnia with a sub-study of the effect of XXXX on stable Type II Diabetes Mellitus: a one year, multi center, randomized, double-blind, placebo-controlled study.
- An Inhaled Mealtime Insulin with the XXXX plus Pioglitazone vs. Pioglitazone alone in Type 2 Diabetes: A 26-Week, Open-Label, Multicenter, Randomized, Parallel Trial to Investigate Efficacy and Safety
- Inhaled Mealtime Insulin with the XXXX Plus Metformin and Glimepiride vs. Rosiglitazone Plus Metformin and Glimepiride in Type 2 Diabetes: A 26-Week, Open-Label, Multicenter, Randomized, Parallel Trial to Investigate Safety and Efficacy

2006

- A Phase I, double blind, placebo-controlled single center trial to assess the safety, tolerability and pharmacokinetics of single dose and multiple dose escalations of XXX in healthy subjects.

- The Relative Bioavailability of Two Amphetamine Transdermal Systems (ATS) to XXXX 10 mg Orally Administered Capsule.

1995

- Principal Investigator, An Open-Label, Randomized, Comparative, Multicenter Study of Clinafloxacin Versus a Ceftazidime-Based Regimen in the Treatment of Nosocomial Pneumonia. (Parke-Davis)

1994

- Principal Investigator, Sparfloxacin Use in Community-Acquired Pneumonia. (Rhône-Poulenc Rorer)
- Principal Investigator, Sparfloxacin Use in Chronic Bronchitis. (Rhône-Poulenc Rorer)
- Principal Investigator, Efficacy and Tolerability of an Improved Influenza Vaccine in Elderly Patients. (Wyeth/Ayerst)

1990

- Principal Investigator, Efficacy of Intravenous Fleroxacin. (Hoffman-LaRoche)
- Investigator, Evaluation of Treatment with IV Cefuroxime followed by Oral Cefuroxime Axetil in Patients with Community Acquired Pneumonia (Glaxo)
- Co-Principal Investigator, Cholesterol and Acute Recurrent Events; 5 Year Outcome Study. (Bristol-Meyers)

1989

- Principal Investigator, Faculty Development in General Internal Medicine. (U.S. Public Health Service)

1987

- Principal Investigator, Geriatric AHE Curriculum Development Grant

1985

- Principal Investigator, VA Cooperative Study #189 'Efficacy of Pneumococcal Vaccine in High Risk Patients'

1981

- Principal Investigator, VA Merit Review, Macrophage-Lymphocyte Interaction in the Compromised Host.

1978

- Principal Investigator, VA Regional Advisory Grant, Micro-methods in Cellular Immunity.

1973

- Principal Investigator, VA Regional Advisory Grant Fluorescent Microscopy in the Diagnosis of Gonococcal Arthritis.

MAJOR CONSULTANTSHIPS AND ACTIVITIES

- 1974 -1976 Consultant Physician
New York City Health Department
- 1977 -1980 Special Consultant
Chesapeake Physicians, PA

- 1977 - 1994 Consultant Physician
St. Joseph Hospital. Baltimore, Maryland
- 1977 - 1985 Consultant Physician and Chairman
Infectious Control Committee
Lutheran Hospital, Baltimore, Maryland
- 1979 - 1996 Member Committee on Health Care in Prisons and Jails The Medical
Care Section of the American Public Health Association
- 1980- 1982 Consultant
DeKalb County Prison Project
Atlanta, Georgia
- 1980 - 1983 Consultant Physician
Maryland Department of Health an Mental Hygiene
- 1980 - 1990 Consultant, National Institute of Corrections
- 1982 - 1988 Consultant, Department of Corrections
Government of the District of Columbia
- 1985 - 1995 Consultant Physician and Chairman
Infection Control Committee, Montebello Hospital
Baltimore, Maryland
- 1986 - 1989 Consultant Physician, Baltimore City Jail
- 1987 -- 1988 Interim Medical Director
John L. Deaton Hospital and. Medical Center
Baltimore. Maryland
- 1988 Consultant, New York State Department of Health
- 1991 International Health Task Force to Kuwait

COMMITTEE ACTIVITIES AND OTHER SERVICES

- 1976 - 1980 Chairman - Medical Education. Committee, Baltimore VA Medical
Center
- 1980 - 1985 Member - Planning and Executive Committees. VA Cooperative Study
for Evaluation of Pneumococcal Vaccine in High Risk Patients
- 1982 - 1985 Member, VA Medical District Planning Process Committee
- 1982 - 1985 Member, VA Chiefs of Ambulatory Care Strategic Planning Committee
- 1994 - 1996 Chairman, Clinical Executive Board, Baltimore VA Medical Center
- 1994 - 1997 Chairman, Medical Executive Committee, Baltimore VA Medical
Center
- 1995 - 2004 Member, Executive Leadership Council, Veteran's Integrated Services
Network #5.
- 1997 - 2004 Chairman, Executive Committee of the Medical Staff, VA Maryland
Health Care System

- 1997 - 2004 Chairman, Executive Performance Improvement Council, VA Maryland Health Care System
- 1998 - 2000 Member, VISN 12 Options Study Task Force
- 1998 - 2002 Chairman. VISN 5 Primary Care Task Force
- 1998 - 2002 Member, Department of Veterans Affairs National Strategic Planning Committee
- 1977 -1978 Member-Ambulatory Medical Audit Committee, VA Medical Center and University of Maryland Hospital
- 1978 - 1979 Member-Departmental Review Committee, University of Maryland School of Medicine
- 1979 - 1984 Member - Curriculum Committee, University of Maryland School of Medicine
- 1979 - 1984 Member - First Year Committee, University of Maryland School of Medicine
- 1979 - 1984 Member - Second Year Committee1 University of Maryland School of Medicine
- 1980 - 1984 Member - Medical School Council, University of Maryland School of Medicine
- 1984 - 2004 Division Heads Committee, Department of Medicine, University of Maryland School of Medicine
- 1984 - 1994 Post Graduate Education Committee. University of Maryland School of Medicine
- 1985 - 1986 Chairman. Ambulatory Care Task Force, University of. Maryland at Baltimore
- 1986 - 1987 Member, University of Maryland and Kernan Hospitals Program Development Committee
- 1987 - 1988 Member, Ad Hoc Space Committee, University of Maryland School of Medicine
- 1989 - 1990 Member, Executive Committee of Geriatric Fellowship Program, University of Maryland School of Medicine
- 1989 - 1990 Chairman, Geriatrics Task Force, University of Maryland at Baltimore
- 1990 - 1991 Member. Primary Care Task Force University of Maryland at Baltimore
- 1990 - 1991 Member, UMAB Coordinating Planning Committee for Statewide Prevention of Heart Disease, Stroke and Cancer
- 1990-1992 Chairman, Curriculum Task Force, VA Model Clinical Site University of Maryland at Baltimore
- 1990 - 1994 Member, GGEAR Education Sub-Committee, University of Maryland at Baltimore
- 1991 - 1992 Chairman, Peer Review Committee, Department of Psychiatry Clinical Clerkship Course

- 1991 - 1994 Member, Community Health Workers Outreach Program Advisory Committee and. Practitioners Panel, University of Maryland School of Pharmacy

- 1994 - 2004 Member, University of Maryland Executive Committee

- 2009 Member, Governor of Maryland international Advisory Council

PUBLICATIONS

Books and Book Chapters

- Novick, L and Al-Ibrahim, MS. Health Problems in the Prison Setting. Springfield, Chicago. Charles C. Thomas. 1977
- Al-Ibrahim, MS. In vitro effects of levamisole on human mononuclear phagocytes. In: Chirigos, M. ed. Progress in Cancer Research and Therapy. New York, Raven Press, 1978: 39- 47.
- Al-Ibrahim, MS: Tularemia. In: Conn, Howard F., ed. Current Therapy. Philadelphia, W.B. Saunders Co., 1982: 80-81.
- Al-Ibrahim, MS and Furth, P. Prevention and Management of Infection in the Peri-operative Period. In: Wolfsthal, SD, ed., Medical Peri-operative Management '89/'90. Norwalk, Conn., Appleton & Lange, 1989: 48-83.
- Rogers, ER and Al-Ibrahim, MS. The Geriatric Patient. In: Wolfsthal, SD ed., Medical Peri-operative Management '89/' 90. Norwalk, Conn, Appleton & Lange, 1989: 327-336.
- Al-Ibrahim, MS and Gross, JY. Tobacco Use. In: Walker H.K, Hall WD, Iurst 1W., eds. Clinical Methods. Stoneham, MA, Butterworth Publishers, 3rd. ed. 1990: 214-21.6.

Publications (Refereed)

- Martin DC, Arnold JD Clyde DF, and Al-Ibrahim, MS. A quinoline methanol (WR 30090) for treatment of acute malaria. *Antimicrob Agents Chemother.* 3(2):214-219, 1973.
- Al-Ibrahim MS and 1-Tolzman RS. Probable Chloroquine Resistant Malaria, New York. *MMWR.* 22:357, 1973.
- Al-Ibrahim MS and Holzman, RS. Bilateral pleural effusions with plasmodium falciparum infection. *Am J Trop Med Hyg.* 1975; 24(1): 910-213.
- Al-Ibrahim MS, Chandra R, Valentine F, and Lawrence HS. A micromethod for evaluation of the phagocytic activity of human macrophages by ingestion of radio-labeled polystyrene particles. *J Immuno Methods.* 1976; 10:207-219.
- Al-Ibrahim MS and Holzman RS. Treatment of Bacteroides endocarditis with carbenicillin. *Am J Med Sci.* 1977; 273(1):105-107.
- Al-Ibrahim MS, Holzman RS, and Lawrence HS. Concentrations of Levamisole required for enhanced proliferation of human Lymphocytes and phagocytosis by macrophages. *J Infect Dis.* 1977; 135(4):517-523.
- Dutta SK and Al-Ibrahim MS. Immunological studies in acute pseudo membranous esophageal candidiasis. *Gastroenterology.* 1978; 75:292-296.
- Al-Ibrahim MS, Valentine FF and Lawrence HS. Activated lymphocytes depress phagocytosis of latex particles by human monocyte-macrophages. *Cell Immunol .* 1978;41:217-230.
- Holly HP and Al-Ibrahim MS. Cerebrospinal fluid eosinophilia following myelography. *JAMA.* 1979;242:2432-2433.
- Hoover DL and Al-Ibrahim MS. Use of glucosamine incorporation to measure human macrophage activation. Activation by antigen-stimulated lymphocytes and correlation with delayed hypersensitivity. *Cell Immunol.* 1980;53:182-184.
- Freeman R, Gollub RE, Woiski M, Gschwend JA and Al-Ibrahim, MS. Planning health services for a City Jail: Impact of contractual services on men's sick call, *Medical Care.* 1981;19:410-418.

- Al-Ibrahim MS, Hawthorne P, Freeman R, Kelly G and Fox L. Utilization of Physicians Assistants in a Large Urban Jail: Clinical design and cost considerations. *J Prison Health*. 1981;1(2):88-96.
- Hynak MT, Al-Ibrahim MS and Russell, R: Nutritional status and pulmonary function in patients with chronic obstructive lung disease. *Nutrition Research*. 1981; 1:461-466.
- Simberkoff MS, Lukaszewskj M, Cross A, Al-Ibrahim MS, Baltch A, Smith R, Geiseler PJ, V Nadler J, Richmond AS. Antibiotic-resistant isolates of *Streptococcus Pneumoniae* from clinical specimens: a cluster of serotype 19A organisms in Brooklyn, New York. *J Infect Dis*. 1986;153:78-82.
- Simberkoff MS, Cross AP, Al-Ibrahim MS, Baltch AL, Geiseler PJ, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS, and Von Eckhout JP. Efficacy of Pneumococcal vaccine in high-risk patients: Results of a Veterans Administration cooperative study. *N Engl J Med*. 1986;315: 1318-1327.
- Page AEK, Walker-Bartnick L, Taler GA, Snow DA, Wertheimer DW, and Al-Ibrahim, MS. A program to teach house calls for the elderly to fourth-year medical students. *J Med Ed*. 1988;63(1):51- 58.
- Vlahov D, Myers AH, Al-Ibrahim MS. Epidemiology of falls among patients in a rehabilitation hospital. *Arch Phys Med Rehabil*. 1990;71:8-12.
- Mackowiak P, Al-Ibrahim MS, Barish R, Bernhard WN, et. al. Journey of the Maryland International Health Task Force to Post-War Kuwait: May 19-27, 1991. *Mil Med J*. 1992;41:407-412.
- Bernhard WN, Barish R, Al-Ibrahim MS, and Flynn, JP. War crimes during the Persian Gulf War. *Mil Med*. 1992;12:667-669.
- Hemani A, Al-Ibrahim MS, Rastegar, Hill C. Diagnostic Utilization Differ by Type of Primary Care Physician. *J Gen Intern Med*. 1997;12(Sup1):73.
- Fedele DJ, Hooper FJ, Chu KP, Kinoshian B, Al-Ibrahim, MS. Relationship of self-reported oral health and nutritional risk among hospitalized older adults. *J Public Health Manag Pract*. 1998;4(3):57-63.
- Hemani A, Rastegar D, Hill C, Al-Ibrahim MS. A comparison of resource utilization in nurse practitioners and physicians. *Eff Clin Pract*. 1999;2(6):258-265.
- Thorne CD, Curbow B, Oliver M, Al-Ibrahim MS, McDiarmid M. Terrorism Preparedness Training for Non-clinical Hospital Workers: Empowering Them to Take Action. *J Occup Environ Med*. 2003;45:333-337.
- Thorne CD, Oliver M, Al-Ibrahim MS, Gucer PW, McDiarmid MA. Terrorism-preparedness training for non-clinical hospital workers: tailoring content and presentation to meet workers' needs. *J Occup Environ Med*. 2004;46(7):668-676.
- Arora M, Falsafi N, Al-Ibrahim MS, Sawyer, Siegel E, Joshi A, Finkelstein J. Evaluation of CoVISTA – an automated vital sign documentation system – in an inpatient hospital setting. *AMIA Annual Symp Proc*. 2005;885.
- Al-Ibrahim MS. Cardiovascular Disease Risk Assessment in Reservists: A Model VA- DOD Sharing Program. *Manuscript in preparation*.
- Al-Ibrahim MS, Loudon M. Can a Public Hospital Survive in a Cost-Driven Changing Environment? *Manuscript in preparation*.
- Smith LR, Wloch MK, Ye M, Reyes LR, Boutsabouatoy S, Dunn C; Chaplain JA, Rusadov D, Rolland AP, Fisher CL, Al-Ibrahim M, Kobongo M, Streigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB. Phase I Clinical trials of the study and immunizations of adjuvantral plasmid DNA vaccines encoding influenza A virus HS hemagglutinin. *Manuscript submitted to New England Journal of Medicine*, 2008

Abstracts

- Al-Ibrahim MS, Holzman RS, Lawrence US. Stimulation of Human Macrophages in vitro by Levamisole. *Clin, Res*. 23:286a, 1975.

- Al-Ibrahim MS, Valentine FT, Lawrence HS. Micro-assay for Macrophage Activation in Man. Clin. Res. 24:444a, 1976.
- Hoover JL, Al-Ibrahim MS. Incorporation of ¹⁴C-glucosamine to Assay Human Macrophage Activation: Correlation with delayed Hypersensitivity and Lymphocytes Blastogenesis. Clin. Res. 25:360a, 1977.
- Spitz RD, Currid VR, Baum RA, Al-Ibrahim MS. Depression of Lymphocyte Reactivity by Cirrhotic Plasma. Clin, Res. 27:27 Ia, 1979
- Al-Ibrahim, MS, Kleinman, LS. Inpatient Transfers to a Veterans Administration Medical Center. Clin. Res. 35:728a, 1987
- Al-Ibrahim MS. A Model Veterans Administration/Department of Defense Sharing Agreement Association of Military Surgeons of the United States. Nashville, TN, November 1992.
- Fedele D, Hooper F, Chu KP, Al-Ibrahim M.: Assessment of Oral Health and Nutritional Status in a Cohort of Acutely Ill Hospitalized Patients. [Abstract #23] American Association of Public Health Dentistry 25 Annual Meeting, Orlando, FL, September 25-27 1996.
- Roghman M, Hooper F and Al-Ibrahim M. Infections among Patients in a Home Health Care Setting: Spectrum, Incidence and Risk Factors. At the 35th Annual Meeting of Infectious Disease Society of America. San Francisco, CA. 1997, [Abstract No. 656]
- Lawitz EJ, Sulkowski MS, Jacobson IM, Quinn E, Al-Ibrahim M and others. Safety, tolerability and anti-viral activity of MK-7009, a novel inhibitor of the Hepatitis C virus NS3/4a Protease in patients with Chronic HCV genotype 1 infection. 59th Annual meeting of the American Association for the Study of Liver Disease (AASLD). San Francisco. October 31 – November 4, 2008
- Wloch MK, Ye M, Kehler J, Delarow J, Reyer L, Boutsabouatoy, Dunne C, Rolland A, Chee A, Kitt E, Al-Ibrahim M, Pritchard D, Steigbrigel R, Koboyo M, Mon R, Smith LR. Vaxfection- formulated pandemic influenza DNA vaccines are well tolerated and induce broad and durable HS immune responses in humans . Abstract preserved: DNA Vaccines 2008, Las Vegas, Nevada